GeneSystem Co

GeneSystem Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is 60.37 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 86.34 % — a change of -30.08% (lower).

FCF Conversion

60.37 %

YoY

-30.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of GeneSystem Co is 2025 60.37 % . FCF Conversion Rate (FCF/EBITDA) of GeneSystem Co was 2024 86.34 % . It decreases by -30.08% lower compared to the previous year.

The GeneSystem Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
74.71 KRW
Jan 1, 2019
59.16 KRW
Jan 1, 2020
93.77 KRW
Jan 1, 2021
18.63 KRW
Jan 1, 2022
73.98 KRW
Jan 1, 2023
103.98 KRW
Jan 1, 2024
86.34 KRW
Jan 1, 2025
60.37 KRW
The GeneSystem Co FCF Conversion history
YEARFCF ConversionYoY
60.37 %-30.08%
86.34 %-16.96%
103.98 %+40.55%
73.98 %+297.02%
18.63 %-80.13%
93.77 %+58.50%
59.16 %-20.81%
74.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

FCF Conversion Rate (FCF/EBITDA) of GeneSystem Co is 60.37 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of GeneSystem Co changed from 86.34 % to 60.37 %, representing a -30.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s GeneSystem Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — GeneSystem Co

All Key Metrics — GeneSystem Co